Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Center, Nonrandomized, Open-label Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

NCT05159895 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.

NCT NCT05159895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05159895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Center, Nonrandomized, Open-label Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
Lead sponsor
Dizal Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
September 24, 2021
Completion date
March 30, 2022
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers